Transforming Pharma with End-To-End AI & Robotics | Alex Zhavoronko, CEO of Insilico Medicine
Insilico Medicine is a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems.
Their mission is to extend healthy productive longevity by transforming drug discovery and development with AI.
Previous
Prizing Innovation with XPRIZE CEO Anousheh Ansari
Next
